CRVS · Corvus Pharmaceuticals

The thesis

Corvus Pharmaceuticals' soquelitinib shares are more likely to lag the S&P 500 over the next three months. The one dated test of the eczema case, Angel Pharmaceuticals' 24-patient China cohort, moved from late 2026 to March 2027, which is past this window. The case is settled by that cohort's results, and by the lymphoma trial's futility analysis guided for the first quarter of 2027.

The shares closed at $9.73 on 5 November 2026, the session of the third-quarter report, and at $11.47 on 11 November 2026. That is 57.4% below the 52-week intraday high of $26.95 on 23 January 2026. The price already reflects the delay: the shares recovered after the report, but they remain well under their January level and below their 200-day average of closes.

CEO Richard Miller said on the 5 November 2026 call that the company extended the timeline so all patients can finish 12 weeks of therapy plus a 30-day follow-up while staying blinded. An analyst on the call described the readout as "pushed out by a quarter."

Cash is not the near-term issue. Corvus held $202.9 million in cash, equivalents and marketable securities at 30 September 2026 and guided runway into the second quarter of 2028 (company release, 5 November 2026).

Bullish and bearish views on Corvus Pharmaceuticals, Inc.

The bull case on Corvus Pharmaceuticals, Inc. (CRVS), in brief: cash funds the planned trials. The bear case: the key readout slipped.

Bull case

• Cash funds the planned trials. Corvus held $202.9 million at 30 September 2026, including about $189.4 million of net proceeds from a financing completed 23 January 2026. Management kept its runway guide into the second quarter of 2028 (company release, 5 November 2026).
• Early eczema data were strong. Final Phase 1 results in moderate-to-severe atopic dermatitis showed 75% of patients in the highest-dose, longest-duration cohort reached a 75% improvement in eczema severity (EASI-75), versus 20% on placebo (Corvus second-quarter results, 6 August 2026).
• A third indication produced early responses. All three patients treated for 360 days in the NIAID-sponsored Phase 2 trial in autoimmune lymphoproliferative syndrome (ALPS) discontinued background medications, including steroids, with no grade 3 or 4 adverse events. The data go to the American Society of Hematology (ASH) meeting in December 2026 (company release, 5 November 2026).
• Several readouts sit in 2027. The registrational lymphoma trial's futility analysis is guided for the first quarter of 2027, hidradenitis suppurativa data for the first half of 2027, and the Corvus-run Phase 2 eczema trial topline for the third quarter of 2027 (company release and call, 5 November 2026).

Bear case

• The key readout slipped. The Angel eczema cohort moved from late 2026 to March 2027 (company release and call, 5 November 2026). Until then the case rests on Phase 1 data and a three-patient ALPS result.
• Spending is rising fast. Third-quarter research and development expense was $17.8 million versus $8.5 million a year earlier. The net loss was $20.3 million, or $(0.22) per share, versus $10.2 million (company release, 5 November 2026).
• Cash is falling while data are small. Cash was $215.2 million at 30 June 2026 and $202.9 million at 30 September 2026. The ALPS result comes from three patients and the Angel cohort has 24, so a sample this small cannot establish efficacy.
• Angel is not a wholly owned study. Angel is a privately held, 49%-owned affiliate running trials in China, and Corvus said on 9 June 2026 it has limited ability to estimate Angel's cash runway.

Price setup

The shares closed at $11.47 on 11 November 2026, per daily closes. That is 24.2% lower than three months earlier (the 13 August 2026 close was $15.14). The 52-week intraday high is $26.95 (23 January 2026) and the 52-week closing low is $6.50 (13 January 2026).

The close of $9.73 on 5 November 2026 was followed by $10.54 on 6 November 2026, $11.35 on 9 November 2026, $11.37 on 10 November 2026 and $11.47 on 11 November 2026. The last close sits just above the 50-day average of $11.33 and below the 200-day average of closes. A close above the 200-day average is the level at which the call would be wrong.

No earnings date is pending, since the third-quarter report and 10-Q were filed on 5 November 2026. The company announced on 10 November 2026 that it will take part in the 2026 Jefferies Global Healthcare Conference. The SEC filings reviewed list no insider Form 4 transactions.

Catalysts ahead

• 12 December 2026: ASH Annual Meeting poster of initial soquelitinib ALPS data (meeting runs 12 December to 15 December 2026). Adds a year of follow-up in a rare immune disorder; three patients so far, so it extends the signal without testing it.
• 2027 Q1 (company guidance): Futility analysis in the registrational Phase 3 lymphoma trial. A stop would remove the registrational program; continuation keeps it alive.
• March 2027 (company guidance): Angel preliminary data from atopic dermatitis cohort 1 (24 patients). The central test of the eczema signal; the date moved from late 2026.
• 2027 Q3 (company guidance): Topline from the Corvus-run Phase 2 eczema trial. The first eczema result from a trial Corvus runs itself.

What would change the view

A daily close above $14.09, which would put the shares over their 200-day average of closes and show them leading the S&P 500 again; positive Angel eczema cohort 1 results in March 2027 would also show the shares leading.

What it trades with

Corvus has no product revenue and trades on clinical results and financing news. Its shares track small and mid-cap clinical-stage biotech and the funding conditions for that group, rather than the broader market's earnings cycle. Angel's China data and the NIAID-run ALPS trial are the two results that depend on parties outside Corvus's direct control.